Truist analyst Jailendra Singh raised the firm’s price target on Iqvia (IQV) to $290 from $265 and keeps a Buy rating on the shares. Iqvia enters 2026 with stronger demand visibility and a healthier operating backdrop, supported by improved book-to-bill ratios, RFP flow, and pipeline clarity, alongside stable TAS trends and continued growth in Consulting & Analytics, the analyst tells investors in a research note. Margins are expected to modestly expand through automation and efficiencies, reinforcing Iqvia’s position as a preferred CRO name due to its scale, diversified clients, and financial flexibility.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA Holdings: Positioned for Growth with Strategic Innovations and Industry Recovery
- Iqvia price target raised to $273 from $254 at Stifel
- Iqvia price target raised to $260 from $245 at BofA
- Iqvia price target raised to $230 from $200 at Barclays
- IQVIA Holdings Amends Credit Agreement for Refinancing